Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Aparicio

Carlos Aparicio, Miami, FL US

Patent application numberDescriptionPublished
20080233553Method and Apparatus for Separating and Harvesting Cells From a Whole Blood Sample - An automated method and apparatus for separating and harvesting cells of interest, e.g., mononuclear cells, in a whole blood sample. The method of the invention uses the aspirating/dispensing probe of an automated sample preparation instrument to underlay a density gradient medium beneath a whole blood sample in a centrifugation tube, and the same probe is used to harvest cells of interest from a cell layer formed in the tube as a result of a centrifugation step. In harvesting cells, the probe is advanced inside the tube by a fixed, predetermined distance at which the probe tip (i.e., its aspiration port) is known to be located at, or within a predetermined distance below, the bottom of the cell layer. A predetermined volume of liquid is then aspirated through the probe tip, whereby most cells of interest (and more than 90% of those cells that can be harvested by a flawless manual method) are removed from the cell layer and collected for analysis. Preferably, the probe is caused to move laterally with respect to the tube during the aspiration of the cell layer, whereby cells offset from the center of the container are readily harvested.09-25-2008

Carlos Avila Aparicio, Madrid ES

Patent application numberDescriptionPublished
20090292406METHODS AND SYSTEMS FOR REDUCING THE PHENOMENON OF STRUCTURAL COUPLING IN THE CONTROL SYSTEM OF AN IN-FLIGHT REFUELLING BOOM - A method for controlling a boom (11-26-2009

Ester Martin Aparicio, Moralzarzal-Madrid ES

Patent application numberDescriptionPublished
20090124686GSK-3 INHIBITORS - The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3β, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus.05-14-2009

Francisco Dominguez Aparicio, Vigo (pontevedra) ES

Patent application numberDescriptionPublished
20080252050Airbag cover with an emblem - The present invention relates to an airbag cover (10-16-2008

Marta Aparicio, Rockville, MD US

Patent application numberDescriptionPublished
20120129775ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE - Methods of inhibiting undesired angiogenesis are provided, which methods include administering to a subject a therapeutically effective amount of at least one of the compounds described herein, or a pharmaceutically acceptable salt thereof.05-24-2012

Samuel Aparicio, Vancouver CA

Patent application numberDescriptionPublished
20100158807RECEPTOR - We disclose a method of treating or preventing a disease selected from the group consisting of: a bladder disease, a bladder disorder, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, including overflow and urge incontinence, urinary urge, cystitis, including interstitial cystitis and overactive bladder.06-24-2010
20100272647RECEPTOR - We disclose BACH G-protein coupled receptor (GPCR) polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof Nucleic acids capable of encoding BACH polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID No. 1, SEQ ID No.2 or SEQ ID NO: 4 or a mouse BACH genomic sequence (SEQ ID NO: 10).10-28-2010
20100311077Use of GPR100 Receptor in Diabetes and Obesity Regulation - We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, the method comprising determining whether a candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which the Gpr100 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5, or a sequence which is at least 90% identical thereto.12-09-2010

Samuel Aparicio, Cambridge GB

Patent application numberDescriptionPublished
20080269118Use of Gpr100 receptor in diabetes and obesity regulation - We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, the method comprising determining whether a candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which the Gpr100 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5, or a sequence which is at least 90% identical thereto.10-30-2008

Patent applications by Samuel Aparicio, Cambridge GB

Sergio Paredes Aparicio, Barcelona ES

Patent application numberDescriptionPublished
20080275038Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists - The present disclosure relates to imidazopyridine derivatives of formula (I):11-06-2008

Takako Aparicio, San Jose, CA US

Patent application numberDescriptionPublished
20100000899MEDICATION BLISTER PACK WITH EMBEDDED USER INTERFACE - A personal medication package is provided with an embedded user interface. The medication package includes an array of storage compartments for storing medication as well as visual indicia that is integrated into the medication package. The visual indicia are formed from color changing ink that is deposited onto the medication package. Consequently, the medication package can be manufactured and disposed of in an ecologically friendly manner.01-07-2010

Yvette E. Aparicio, Forest Park, IL US

Patent application numberDescriptionPublished
20090180607SKILLS-BASED COMMUNICATION ROUTING - A skills-based method for routing an incoming communication includes determining a task associated with the incoming communication. The method also includes routing the incoming communication, based on the task, to be serviced by a pool of selected agents. The pool of selected agents includes agents from a first virtual group. The method further includes adding agents from a second virtual group to the pool of selected agents when the incoming communication has not been serviced before a waiting time exceeds a predetermined time.07-16-2009